ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Is re-irradiation combined with chemotherapy an option for inoperable local recurrence of previously irradiated breast cancer? A collection of cases.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rate of locoregional recurrence after primary therapy remains at 5-15%. Ipsilateral recurrences are most commonly located in the residual breast or chest wall, followed by isolated nodal axillary and supraclavicular recurrences at 1-3%. In pre-irradiated patients with inoperable recurrences, re-radio(chemo)therapy can achieve sufficient local tumor control.
methodsAll inoperable patients with histologically confirmed locoregional recurrence (LRR) who underwent salvage radio(chemo)therapy at the University Medical Center Freiburg were included in this analysis. A descriptive assessment of toxicity and oncological endpoints was performed.
resultsA total of seven patients were identified. The LRRs were located as follows: two in the chest wall, three parasternal/sternal, and two supraclavicular. The LRRs occurred after a median of 99 (3-311) months after completion of primary therapy. In four patients, additional osseous involvement (per continuitatem) was diagnosed. The mean dose of prior radiation was 59.7 Gy. All patients received normofractionated percutaneous radiotherapy, with a simultaneous integrated boost with a single dose of 1.7-2 Gy up to a total dose of 50.4-60 Gy, if necessary. Five patients received concomitant chemotherapy with 5‑fluorouracil (FU)/capecitabine. Staging and target volume definition were based on PET-CT or MRI imaging. The median follow-up was 14.8 (1-76) months. No high-grade toxicity ≥ 3 was observed. Acute and chronic toxicity grade 1-2 was limited to radiodermatitis, fatigue, restriction of arm elevation, and pain. Local tumor control was achieved in all patients. Visceral metastasis occurred in one woman.
conclusionRe-irradiation with concurrent chemotherapy in inoperable LRR can achieve reliable local control. Our approach provides additional support for the existing evidence regarding the oncological benefit of combined postoperative radiotherapy and capecitabine in patients with triple-negative breast cancer. Given the established clinical tolerability of re-irradiation protocols, future efforts must prioritize the standardization of concurrent systemic treatments to optimize both safety and therapeutic outcomes in this setting.
Indexed as
Identifiers
42012680What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.